Gan & Lee Pharmaceuticals. (SHA:603087)

China · Delayed Price · Currency is CNY

65.47

-2.96 (-4.33%)

Aug 24, 2026, 3:00 PM CST

-4.49% (1Y)

Market Cap	38.97B -4.2%
Revenue (ttm)	3.95B +13.7%
Net Income	1.02B +23.3%
EPS	1.73 +22.7%
Shares Out	595.20M
PE Ratio	37.79
Forward PE	25.38
Dividend	1.00 (1.38%)
Ex-Dividend Date	May 29, 2026

Volume	10,725,855
Open	68.44
Previous Close	68.43
Day's Range	65.00 - 68.68
52-Week Range	51.51 - 82.25
Beta	0.27
Analysts	Strong Buy
Price Target	72.50 (+10.74%)
Earnings Date	Aug 26, 2026

About SHA:603087

Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the development, production, and commercialization of insulin analogs and medical devices in China. Its products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro injection; Prandilin 25, an insulin lispro mix 75/25 injection; Rapilin, an insulin aspart injection; Rapilin 30, an insulin aspart 30 injection; and Similin 30, a mixed protamine human insulin injection. The company also offers GanleePen, an insulin injection device; and GanleeFine, an insu... [Read more]

Industry Medical Instruments & Supplies

Sector Healthcare

Founded 1998

Employees 5,309

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 603087

Full Company Profile

Financial Performance

In 2025, SHA:603087's revenue was 4.05 billion, an increase of 33.06% compared to the previous year's 3.05 billion. Earnings were 1.14 billion, an increase of 86.05%.

Financial Statements

Analyst Summary

According to 3 analysts, the average rating for 603087 stock is "Strong Buy." The 12-month stock price target is ¥72.50, which is an increase of 10.74% from the latest price.

Price Target

¥72.50

(10.74% upside)

Analyst Consensus: Strong Buy

Stock Forecasts